Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets and technologies. The two companies already share a partner in common: both have therapeutic candidates that use the gene-editing capabilities of CRISPR Therapeutics.
In a deal worth up to $25 million for ViaCyte, the companies will work together to create allogeneic stem cell therapies to treat the disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Through a new partnership with the maker of GORE-TEX, San Diego's ViaCyte is looking to finetune its PEC-Encap combination device that could one day offer a functional cure for type 1 diabetes.
San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process. As part of the deal, the pharma giant gains rights to evaluate clinical efficacy of ViaCyte’s Type 1 diabetes treatment – an artificial […]